$SNDX News

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Syndax Pharmaceuticals Suffers Pipeline Blow

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Claude AI Just Bought These 2 Pharma Stocks

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in September Investor Conferences

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?

Syndax (SNDX) Q2 2026 Earnings Call Transcript

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38